Tiziana Life Sciences Ltd
TLSA
$0.81
$0.00991.24%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.91% | 57.25% | 505.21% | 1,271.34% | 5,556.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.81% | 1.30% | 23.30% | 24.65% | 25.97% |
| Operating Income | 15.81% | -1.30% | -23.30% | -24.65% | -25.97% |
| Income Before Tax | 14.85% | 3.01% | -11.98% | -24.34% | -37.78% |
| Income Tax Expenses | -- | -- | -- | 113.86% | -- |
| Earnings from Continuing Operations | 29.60% | 9.97% | -14.90% | -41.36% | -78.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.60% | 9.97% | -14.90% | -41.36% | -78.68% |
| EBIT | 15.81% | -1.30% | -23.30% | -24.65% | -25.97% |
| EBITDA | 15.84% | -1.28% | -23.30% | -24.68% | -26.02% |
| EPS Basic | 28.86% | 9.25% | -15.37% | -42.23% | -80.92% |
| Normalized Basic EPS | 21.63% | 4.97% | -16.29% | -25.64% | -35.58% |
| EPS Diluted | 28.86% | 9.25% | -15.37% | -42.23% | -80.92% |
| Normalized Diluted EPS | 21.63% | 4.97% | -16.29% | -25.64% | -35.58% |
| Average Basic Shares Outstanding | -0.78% | 0.06% | 0.93% | 0.13% | -0.65% |
| Average Diluted Shares Outstanding | -0.78% | 0.06% | 0.93% | 0.13% | -0.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |